Show simple item record

dc.contributor.authorAy, Mustafa
dc.contributor.authorYÜCE, Servet
dc.contributor.authorBEKTAŞ, Murat
dc.contributor.authorKilic, Muhammed Ikbal
dc.contributor.authorUyar, Muhammed Hamdi
dc.contributor.authoroender, Mustafa Erkut
dc.date.accessioned2023-10-10T11:30:10Z
dc.date.available2023-10-10T11:30:10Z
dc.date.issued2023
dc.identifier.citationBEKTAŞ M., YÜCE S., Ay M., Uyar M. H., oender M. E., Kilic M. I., "High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center", INFLAMMOPHARMACOLOGY, cilt.31, sa.2, ss.787-797, 2023
dc.identifier.issn0925-4692
dc.identifier.othervv_1032021
dc.identifier.otherav_14bab43f-1d5e-4445-a78a-29d6dae97ec5
dc.identifier.urihttp://hdl.handle.net/20.500.12627/189753
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/14bab43f-1d5e-4445-a78a-29d6dae97ec5/file
dc.identifier.urihttps://doi.org/10.1007/s10787-023-01138-8
dc.description.abstractBackgroundIn COVID-19, severe disease course such as need of intensive care unit (ICU) as well as development of mortality is mainly due to cytokine storm. In this study, we aimed to evaluate the high-dose intravenous anakinra treatment response and outcome in patients with severe and critically ill COVID-19 compared to standard of care.MethodsThis retrospective observational study was carried out at a tertiary referral center. The study population consisted of two groups as follows: the patients receiving high-dose intravenous anakinra (anakinra group) between 01.09.2021 and 01.02.2022 and the patients treated with standard of care (SoC, control group) as historical control group who were hospitalized between 01.07.2021 and 01.09.2021.ResultsAfter the propensity score 1:1 matching, 79 patients in anakinra and 79 patients in SoC matched and were included into the analysis. Mean +/- SD patient age was 67.4 +/- 16.7 and 67.1 +/- 16.3 years in anakinra and SoC groups, respectively (p = 0.9). Male gender was 38 (48.7%) in anakinra and 36 (46.2%) in SoC (p = 0.8). Overall, ICU admission was in 14.1% (n = 11) and 30.8% (n = 24) (p = 0.013; OR 6.2), intubation in 12.8% (n = 10) and 16.7% (n = 13) patients (p = 0.5), and 14.1% (n = 11) and 32.1% (n = 25) patients died in anakinra and control groups, respectively (p = 0.008; OR 7.1).ConclusionIn our study, mortality was lower in patients receiving anakinra compared to SoC. Intravenous high-dose anakinra is safe and effective treatment in patients with severe and critical COVID-19.
dc.language.isoeng
dc.subjectSağlık, Toksikoloji ve Mutajenez
dc.subjectFizik Bilimleri
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectTOKSİKOLOJİ
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectMeslek Bilimleri
dc.subjectFarmasötik Toksikoloji
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectToksikoloji
dc.subjectFarmakoloji
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji (tıbbi)
dc.subjectİlaç Rehberleri
dc.subjectGenel İmmünoloji ve Mikrobiyoloji
dc.titleHigh-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center
dc.typeMakale
dc.relation.journalINFLAMMOPHARMACOLOGY
dc.contributor.departmentAksaray Training & Res Hosp , ,
dc.identifier.volume31
dc.identifier.issue2
dc.identifier.startpage787
dc.identifier.endpage797
dc.contributor.firstauthorID4305189


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record